Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019006047 - TDO2 AND IDO1 INHIBITORS

Publication Number WO/2019/006047
Publication Date 03.01.2019
International Application No. PCT/US2018/039880
International Filing Date 28.06.2018
IPC
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/437 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4188
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4188condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Applicants
  • GENENTECH, INC. [US]/[US]
  • NEWLINK GENETICS CORPORATION [US]/[US]
  • PEI, Zhonghua [US]/[US] (MN)
  • PARR, Brendan [US]/[US] (MN)
  • LIU, Wendy [US]/[US] (MN)
  • PASTOR, Richard [US]/[US] (MN)
  • GAZZARD, Lewis [GB]/[US] (MN)
  • JAIPURI, Firoz [IN]/[US] (MN)
  • KUMAR, Sanjeev [IN]/[US] (MN)
  • POTTURI, Hima [IN]/[US] (MN)
  • WU, Guosheng [US]/[CN] (MN)
  • LIN, Xingyu [CN]/[CN] (MN)
  • CHU, Yanyan [CN]/[CN] (MN)
  • YUEN, Po-wai [US]/[CN] (MN)
Inventors
  • PEI, Zhonghua
  • PARR, Brendan
  • LIU, Wendy
  • PASTOR, Richard
  • GAZZARD, Lewis
  • JAIPURI, Firoz
  • KUMAR, Sanjeev
  • POTTURI, Hima
  • WU, Guosheng
  • LIN, Xingyu
  • CHU, Yanyan
  • YUEN, Po-wai
Agents
  • LEONARD, Nicholas, M.
Priority Data
PCT/CN2017/09052628.06.2017CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TDO2 AND IDO1 INHIBITORS
(FR) INHIBITEURS DE TDO2 ET IDO1
Abstract
(EN) Presently provided are inhibitors of TD02 and IDOl and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3- dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
(FR) La présente invention concerne des inhibiteurs de TDO2 et de IDO1 et des compositions pharmaceutiques de ceux-ci, utiles pour moduler une activité de la tryptophane 2,3 dioxygénase et de l'indoléamine 2,3- dioxygénase 1 ; traiter l'immunosuppression ; traiter des états pathologiques qui sont améliorés par inhibition de la dégradation de tryptophane ; augmenter l'efficacité d'un traitement anticancéreux qui consiste à administrer un agent anticancéreux ; traiter l'immunosuppression spécifique à une tumeur associée au cancer.
Related patent documents
Latest bibliographic data on file with the International Bureau